Newsroom
Sorted by: Latest
-
Quelques semaines seulement après son lancement, la plateforme de trading sans risque UpsideOnly dépasse les 100 000 utilisateurs
SAN FRANCISCO--(BUSINESS WIRE)--Perpetuals.com Ltd (Nasdaq : PDC) a annoncé aujourd’hui qu’UpsideOnly, sa plateforme axée sur le trading sans risque et les prévisions de marché, avait enregistré une forte hausse du nombre d’inscriptions de nouveaux utilisateurs, franchissant le cap symbolique des 100 000 traders quelques semaines seulement après son lancement le 19 mai dernier. UpsideOnly permet aux utilisateurs d’effectuer des prévisions sur l’évolution des marchés mondiaux des actions, des ma...
-
Franklin Resources, Inc. Announces Preliminary Month-End Assets Under Management
SAN MATEO, Calif.--(BUSINESS WIRE)--Franklin Resources, Inc. (Franklin Templeton) (NYSE: BEN) today reported preliminary month-end assets under management (AUM) of $1.79 trillion at June 30, 2026, compared to $1.78 trillion at May 31, 2026. This month’s increase in preliminary AUM reflected long-term net inflows of $9 billion, partially offset by the net impact of market, distributions, and other. Long-term flows at Western Asset Management1 were flat. For the quarter ended June 30, 2026, preli...
-
CRNX Stock Alert: Halper Sadeh LLC is Investigating Whether Crinetics Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) to Vertex Pharmaceuticals Incorporated for $85.00 per share in cash. Halper Sadeh encourages Crinetics shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Crinetics a...
-
EPR Properties Second Quarter 2026 Earnings Conference Call Scheduled for July 30, 2026
KANSAS CITY, Mo.--(BUSINESS WIRE)--EPR Properties (NYSE: EPR) will release Q2 2026 financial results on July 29, 2026 & earnings call will be on Thurs., July 30, 2026 at 8:30 a.m. ET....
-
Resumen: Klarna solicita una licencia bancaria en Estados Unidos
NUEVA YORK--(BUSINESS WIRE)--Klarna (NYSE: KLAR), el banco digital global y proveedor de soluciones de pago flexibles, anunció hoy que ha presentado las solicitudes correspondientes ante el Departamento de Instituciones Financieras de Utah y la Corporación Federal de Seguro de Depósitos (FDIC) para crear Klarna Bank USA, un banco industrial regulado por el estado de Utah. Klarna opera como banco autorizado en Europa desde 2017 y presta servicio a sus clientes en Estados Unidos a través de una a...
-
Agenus在ESMO GI 2026大会上公布BOT+BAL的里程碑式数据,结果显示,对于无活动性肝转移的难治性MSS转移性结直肠癌,三年总生存率达33%
马萨诸塞州列克星敦--(BUSINESS WIRE)--(美国商业资讯)-- 免疫肿瘤创新领域的领导者Agenus Inc. (Nasdaq: AGEN)今日公布了入组满员的C-800-01队列的三年里程碑式1b期数据。该队列评估了经Fc段增强的多功能抗CTLA-4抗体botensilimab (BOT)联合抗PD-1抗体balstilimab在治疗无活动性肝转移的难治性微卫星稳定型(MSS)转移性结直肠癌(mCRC)患者中的疗效。该数据于7月2日在德国慕尼黑举行的2026年欧洲肿瘤内科学会胃肠道肿瘤(ESMO GI)大会上公布。 BOT+BAL方案在既往接受过重度预治疗的患者群体中展现了具有临床意义的长期生存获益。这类患者群体历来从传统免疫检查点抑制剂中获益有限,且在标准治疗进展后很少有持久的治疗方案。随着随访时间的延长,患者的中位总生存期达到21.2个月,三年总生存率为33%,Kaplan-Meier曲线显示在两年后出现平台期。 在相关分析中,针对无活动性肝转移的难治性MSS mCRC,现有的后线标准治疗方案的历史中位总生存期约为10–14个月。这反映出在此类治疗环境中,过去极少有...
-
Samenvatting: Agenus presenteert op ESMO GI 2026 veelbelovende resultaten van BOT+BAL: 33% totale overleving na drie jaar bij refractair MSS-gemetastaseerd colorectaal carcinoom zonder actieve levermetastasen
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), een leider op het gebied van innovatie in de immuno-oncologie, heeft vandaag de Fase 1b-gegevens na drie jaar bekendgemaakt van het volledig ingeschreven C-800-01-cohort (fase 1b). Hierin werd de combinatie onderzocht van botensilimab (BOT) – een multifunctioneel anti-CTLA-4-antilichaam met verbeterde Fc-functie – en balstilimab (BAL) – een anti-PD-1-antilichaam – bij patiënten met refractair microsatelliet-stabiel (MSS) gemetastase...
-
Agenus divulga dados históricos de BOT+BAL mostrando sobrevida global de 33% em três anos em câncer colorretal metastático MSS refratário sem metástases hepáticas ativas no ESMO GI 2026
LEXINGTON, Massachusetts--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), líder em inovação em imuno-oncologia, anunciou hoje dados históricos de três anos da Fase 1b da coorte completa do estudo C-800-01. O estudo avaliou o botensilimab (BOT), um anticorpo multifuncional anti-CTLA-4 com expressão aumentada na região Fc, em combinação com o balstilimab (BAL), um anticorpo anti-PD-1, em pacientes com câncer colorretal metastático (CCRm) refratário, microssatélite estável (MSS), sem metástases hepát...
-
Agenus在ESMO GI 2026大會上公布BOT+BAL的里程碑式資料,結果顯示,對於無活動性肝轉移的難治性MSS轉移性大腸直腸癌,三年整體存活率達33%
麻薩諸塞州萊辛頓--(BUSINESS WIRE)--(美國商業資訊)-- 免疫腫瘤創新領域的領導者Agenus Inc. (Nasdaq: AGEN)今日公布了招募滿員的C-800-01佇列的三年里程碑式第1b期資料。該佇列評估了經Fc段強化的多功能抗CTLA-4抗體botensilimab (BOT)聯合抗PD-1抗體balstilimab在治療無活動性肝轉移的難治性微衛星穩定型(MSS)轉移性大腸直腸癌(mCRC)病患中的療效。該資料於7月2日在德國慕尼黑舉行的2026年歐洲腫瘤內科學會胃腸道腫瘤(ESMO GI)大會上公布。 BOT+BAL方案在既往接受過重度預治療的病患群體中展現了具有臨床意義的長期生存獲益。這類病患群體歷來從傳統免疫檢查點抑制劑中獲益有限,且在標準治療進展後很少有持久的治療方案。隨著隨訪時間的延長,病患的中位整體存活期達到21.2個月,三年整體存活率為33%,Kaplan-Meier曲線顯示在兩年後趨於平穩。 在相關分析中,針對無活動性肝轉移的難治性MSS mCRC,現有的後線標準治療方案的歷史中位整體存活期約為10–14個月。這反映出在此類治療環境中,過去...
-
TCW Strategic Income Fund Announces Monthly Distribution
LOS ANGELES--(BUSINESS WIRE)--The TCW Group, a leading global investment firm, announced today that the TCW Strategic Income Fund, Inc. (NYSE: TSI) has declared a monthly distribution of $0.0283 per share payable on July 31, 2026, to shareholders of record on July 16, 2026.Distributions are based on the Fund’s accumulated net investment income and/or other sources for the applicable month. The Directors continue to monitor conditions and circumstances relating to the distribution of dividends an...